Open Actively Recruiting

Role of Race in Nutritional Approach in Men on ADT

About

Brief Summary

There is a well-documented association between androgen deprivation therapy (ADT) and cardiovascular morbidity. A majority of men on ADT gain weight contributing to an increase in cardiovascular risk factors (CVRFs) and cardiovascular morbidity. Dietary intervention combined with exercise have shown success in reducing weight/fat mass and improving cardiovascular risk factors (CVRF). There is little data on whether African American men would respond to diet and exercise interventions differently from non-Hispanic white men. We will conduct a pilot, controlled two-phase intervention study stratified by race to investigate the following objectives:

  • Compare effect of a hypocaloric, anti-inflammatory diet on changes in fat mass between African- American vs non-Hispanic white men with metastatic prostate cancer on ADT therapy.
  • Compare effect of a hypocaloric, anti-inflammatory diet on changes in cardiovascular risk factors (body weight, lean body mass, waist-to-height ratio, blood pressure, lipids and HbA1C) and inflammatory markers (hs-CRP and cytokines) between African-American vs non-Hispanic white men with metastatic prostate cancer on ADT therapy.
  • Compare effect of a hypocaloric, anti-inflammatory diet on changes in cancer-related fatigue and quality of life between African-American vs non-Hispanic white men with metastatic prostate cancer on ADT therapy.

We will enroll 35 African American and 35 non-Hispanic white men with prostate cancer undergoing ADT therapy. In phase 1, after baseline assessment, men will consume their habitual diet and continue their habitual activity level for 3 months. During phase 2, participants will be instructed to consume a hypocaloric (-500 kcal), anti- inflammatory diet and walk for 1 hour on 3 days per week for 3 months. At baseline, after phase 1 and 2 primary outcome (fat mass) and secondary outcomes (CVRF and inflammatory markers) and tertiary outcomes (cancer-related fatigue and quality of life) will be determined.

Primary Purpose
The main objective of the intervention(s) being evaluated by the clinical trial. Learn more
Other
Study Type
The nature of the investigation or investigational use for which clinical study information is being submitted. Learn more
Interventional
Phase
N/A

Eligibility

Gender
Male
Healthy Volunteers
No
Minimum Age
18 Years
Maximum Age
N/A

Inclusion Criteria:

  • >12 months on ADT
  • Expected continuation of ADT for >6 months upon initiation of study procedures
  • Serum testosterone <50 ng/dL
  • BMI >25
  • Age >18 years old
  • African American and Non-Hispanic white males
  • Subjects must read and sign the Institutional Review Board-approved written informed consent prior to the initiation of any study specific procedures or enrollment. A subject will be excluded for any condition that might compromise the ability to give truly informed consent

Exclusion Criteria:

  • Life expectancy < 1 year
  • Females
  • Radiation or chemotherapy treatment
  • History of diabetes or serious medical condition including uncontrolled hypertension, liver, kidney, and cardiovascular disease
  • Any subject with a screening laboratory value outside of the laboratory normal range that is considered clinically significant for study participation by the investigator
  • Any subject who currently uses tobacco products
  • Any use of >20 g of alcohol per day
  • Any subject who is unable or unwilling to comply with the study protocol
  • Any subject who is unable to provide consent
Study Stats
Protocol No.
22-001730
Category
Prostate Cancer
Contact
  • Irene Gilbuena
Location
  • UCLA Westwood
For Providers
NCT No.
NCT06682390
For detailed technical eligibility, visit ClinicalTrials.gov.